Open an Account
search icon
3
NOTIFICATIONS
Best Algo trading app in India
Bigul

Abbott India Ltd - 500488 - Board Meeting Intimation for Approval Of Unaudited Financial Results Of The Company For The First Quarter Ended On June 30, 2019.

 ABBOTT INDIA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/08/2019 ,inter alia, to consider and approve the text of Unaudited Financial Results of the Company for the first quarter ended on June 30, 2019. Further please note that in terms of Abbott India Code of Internal Procedures and Conduct for Regulating, Monitoring and Reporting of Trading by Insiders and in accordance with the provisions of the Securities and Exchange Board of India (Prohibition of Insider Trading) (Amendment) Regulations, 2019, the Trading Window of the Company remains closed from Monday, July 1, 2019 to Saturday, August 10, 2019 (both days inclusive).
29-07-2019
Bigul

Abbott India Ltd - 500488 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

 Abbott India Limited has informed BSE regarding Loss of Share Certificate / Issue of Duplicate Share Certificate.
29-07-2019
Bigul

Abbott India Ltd - 500488 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

 Abbott India Limited has informed BSE regarding Loss of Share Certificate / Issue of Duplicate Share Certificate.
23-07-2019
Bigul

ABBOTT INDIA LTD. - 500488 - Shareholding for the Period Ended June 30, 2019

 Abbott India Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2019. For more details, kindly Click here
12-07-2019
Bigul

ABBOTT INDIA LTD. - 500488 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

 Abbott India Limited has informed BSE regarding Loss of Share Certificate / Issue of Duplicate Share Certificate.
04-07-2019
Bigul

ABBOTT INDIA LTD. - 500488 - Statement Of Investor Complaints For The Quarter Ended June 2019

 No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 1120 Name of the Signatory :- Krupa AnandparaDesignation :- Company Secretary and Compliance Officer
03-07-2019
Bigul

ABBOTT INDIA LTD. - 500488 - Statement Of Investor Complaints For The Quarter Ended June 2019 (Revised)

 No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 1120 Name of the Signatory :- Krupa AnandparaDesignation :- Company Secretary and Compliance Officer
03-07-2019
Bigul

Abbott India Ltd - 500488 - Closure of Trading Window

 This is to inform you that, in accordance with the provisions of the Securities and Exchange Board of India (Prohibition of Insider Trading) (Amendment) Regulations, 2019, the Trading Window for dealing in the shares of the Company by the Designated Persons and their immediate relatives has closed from today i.e. Monday, July 1, 2019 and the same shall reopen on 48 hours after the declaration of Unaudited Financial Results for the first quarter ended on June 30, 2019.
01-07-2019
Bigul

Abbott India Ltd - 500488 - Submission Of Disclosure On Related Party Transactions For The Year Ended March 31, 2019

 Pursuant to Regulation 23(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed, disclosure of related party transactions on a consolidated basis, in the format specified in the accounting standards for the year ended March 31, 2019. The above disclosure is also available on the website of the Company i.e. www.abbott.co.in This is for your information and record.
25-06-2019
Bigul

Abbott India Ltd - 500488 - Announcement under Regulation 30 (LODR)-Change in Directorate

 Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby intimate you that the Board has approved the re-appointment of Mr Rajiv Sonalker (DIN: 07900178) for a further period with effect from August 8, 2019 upto June 30, 2021, subject to approval of the Shareholders of the Company at the ensuing Annual General Meeting. Mr Sonalker is a Chief Financial Officer (CFO) of the Company. He has over 30 years' of experience in the Pharmaceutical, FMCG and Engineering sectors. Prior to joining Abbott India, he worked with Bristol-Myers Squibb as Director - Finance, Voltas Ltd, Johnson & Johnson, Sanofi - Aventis in India and Germany. He is a Fellow Member of Institute of Chartered Accountants of India. Mr Sonalker does not hold any shares in the Company and not related to any of the Board Directors of the Company.
11-06-2019
Next Page
Close

Let's Open Free Demat Account